Glenmark Pharmaceuticals Ltd has officially launched GLIPIQ® (semaglutide) in India for Type 2 Diabetes Mellitus (T2DM) management, setting a new benchmark in affordability for GLP-1 therapy. The launch represents a significant milestone in making advanced diabetes treatment more accessible to Indian patients through improved cost-effectiveness.

Product Specifications and Pricing

GLIPIQ® introduces a new standard in GLP-1 therapy affordability, addressing one of the primary barriers to advanced diabetes treatment in India. The product is available in two distinct formulations designed to meet different patient needs and treatment stages.

Regulatory Approval and Clinical Evidence

The Central Drugs Standard Control Organization (CDSCO) approved GLIPIQ® following comprehensive clinical evaluation. The approval was based on a multicentre, randomised, comparative, active-controlled, open-label Phase III clinical study conducted specifically in India, demonstrating favourable efficacy and safety outcomes in Indian patients with Type 2 diabetes.

The vial-based formulation features dose-specific syringes designed to enable accessible, flexible, and clinically manageable GLP-1 therapy. This format supports physician-guided dosing aligned to individual patient needs, particularly beneficial during early treatment stages.

Treatment Pathway and Patient Support

Glenmark designed GLIPIQ® to offer a structured treatment pathway combining both vial and pen formats. The vial formulation provides cost-effective treatment initiation, while the pre-filled pen format offers convenience for long-term self-dosing therapy. This dual approach supports treatment continuity, improved adherence, and sustained therapeutic outcomes.

The company launched 'Sankalp', a comprehensive patient support program designed to:

• Support therapy initiations
• Improve patient comfort with injectable treatment
• Enable long-term treatment adherence
• Achieve better health outcomes

Clinical Applications and Benefits

Semaglutide functions as a GLP-1 receptor agonist widely used in Type 2 Diabetes management, particularly for patients with specific comorbidities. The therapy demonstrates broad cardiometabolic benefits beyond glycemic control, making it suitable for patients with:

Management Commentary

Alok Malik, President and Business Head, India Formulations at Glenmark Pharmaceuticals Ltd., emphasized the significance of addressing affordability barriers in advanced diabetes therapy. He highlighted that the vial-based format enables more affordable treatment options while supporting clinically guided initiation and flexible dosing approaches.

The launch builds on Glenmark's existing experience in the GLP-1 category, including their Lirafit™ (Liraglutide) product, demonstrating the company's continued commitment to expanding access to advanced diabetes treatments in the Indian market.

Glenmark Pharmaceuticals Inc., USA has announced the launch of Milnacipran Hydrochloride Tablets across four dosage strengths, marking another significant addition to the company's generic pharmaceutical portfolio in the North American market.

Product Launch Details

The US subsidiary launched Milnacipran Hydrochloride Tablets as an authorized generic to Savella® Tablets across multiple dosage strengths. The product specifications and market positioning are outlined below:

Market Opportunity

According to IQVIA sales data for the 12-month period ending January 2026, the Savella® Tablets market achieved substantial annual sales figures:

Management Commentary

Marc Kikuchi, President & Business Head, North America, expressed enthusiasm about the launch, stating that the company is excited to announce the launch of Milnacipran Hydrochloride Tablets as the authorized generic to Savella® Tablets. He emphasized that this launch further strengthens the company's commitment to bring quality and affordable alternatives for patients to the market.

Product Specifications and Compliance

The launched product adheres to specific regulatory requirements and indications. Glenmark's Milnacipran Hydrochloride Tablets is approved only for the indications listed in Glenmark's approved label. The company has clarified that while IQVIA data obtained covers all approved reference listed drug indications, Glenmark's product is specifically approved for the indications listed in its approved label and is not marketed for all reference listed drug indications.

Strategic Significance

This launch represents Glenmark's continued expansion in the US generic pharmaceutical market, providing healthcare providers and patients with additional treatment options. The authorized generic approach allows the company to offer cost-effective alternatives while maintaining quality standards equivalent to the reference brand product.